Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ocular Therapeutix (OCUL) Misses Q4 EPS by $1.04, Revenues Miss
March 11, 2021 4:04 PM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($1.21), $1.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.35 million versus the consensus estimate of $9.76 million.
The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company, said Antony Mattessich, President... More
